Jason Haas is CFO at Syros Pharmaceuticals, Inc. (SYRS). They have made 5 open-market trades across 3 companies since 2024, most recently 2026-08-12.
CIK 0001883821
2 open-market purchases totalling $312K since 2024, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| LGND | 3,981 | $1.2M |
| ODTX | 62,908 | $1.1M |
| SYRS | 143,427 | $17K |
| Total | $2.3M |
Shares reported on the most recent Form 4, priced at the 2026-08-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LGND | SELL | 2026-08-12 | 2026-08-14 | $292.81 | $2.1M | -2.6% | -4.9% | — |
| LGND | SELL | 2026-06-12 | 2026-06-15 | $255.58 | $1.7M | +18.8% | +15.8% | +9.9% |
| ODTX | BUY | 2026-05-08 | 2026-05-11 | $20.00 | $20K | +2.8% | -7.3% | +28.1% |
| SYRS | SELL | 2024-11-18 | 2024-11-20 | $0.21 | $29K | -13.8% | -31.0% | -32.3% |
| SYRS | BUY | 2024-09-10 | 2024-09-12 | $1.62 | $292K | +7.8% | +10.1% | -86.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.